Skip to Main Content

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus this morning. This calls for celebration with a cup of stimulation, and we are opening a new package of glazed doughnut for the occasion. Meanwhile, our ever-growing to-do list needs attention. Sound familiar? So … here are some items of interest. Have a great day, everyone. …

The European Medicines Agency concluded there is a link between the AstraZeneca (AZN) Covid-19 vaccine and “very rare” but dangerous clotting events reported in a number of countries where the vaccine has been used, events which in some cases have been fatal, STAT says. A safety committee concluded “unusual blood clots with low blood platelets should be listed as very rare side effects.” Regulators stressed the benefits of the vaccine, which was 76% effective at preventing Covid infections in a large U.S.-based study, still outweigh its risks.


AstraZeneca served a legal notice to its manufacturing partner, Serum Institute of India, over delays in supplying its Covid-19 vaccine, The Economic Times tells us. The notice comes after Serum Institute delayed shipment of vaccines to the U.K., and later did not meet its obligations to other countries that are part of the World Health Organization’s COVAX program. Serum Institute has attributed the delay to a government decision to halt vaccine exports.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!